Further investigation of how PARylated PARP1 orchestrates FUS phase separation will deepen our understanding of neurological diseases and cancers caused by mutations in these proteins and may provide the basis for the development of innovative technologies in cancer therapy. This evidence concerns the gene PARP1 and nervous system disorder.